<DOC>
	<DOCNO>NCT00723697</DOCNO>
	<brief_summary>The purpose study assess risk abuse , misuse adverse event related high dose buprenorphine . Approximately 1250 patient take Subutex ( Schering-Plough ) Buprenorphine High Dose ( BHD ) generic ( Arrow Laboratories ) participate study . Data collect use physician questionnaire self evaluation patient questionnaire first visit visit 6 12 month .</brief_summary>
	<brief_title>Observational Study Misuse High Dose Buprenorphine ( SubutexÂ® Generic ) Opiate-Addicted Patients France ( Study P05186AM1 ) ( COMPLETED )</brief_title>
	<detailed_description>Approximately 380 physician participate study . Patients enrol chronological order consultation .</detailed_description>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Eligible patient already prescription Subutex BHD generic , propose prescription Subutex BHD generic first time consult participate physician . The patient must inform orally write via information notice sign . Criteria noneligibility relate contraindication Marketing Authorization ( MA ) Subutex BHD generic</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Subutex</keyword>
</DOC>